Macrophage migration inhibitory factor (MIF) is a cytokine expressed in various cell types,
including hematopoietic, epithelial, endothelial, mesenchymal and neuronal cells. Altered …

Glucocorticoid resistance or insensitivity is a major barrier to the treatment of several
common inflammatory diseases—including chronic obstructive pulmonary disease and …

Glucocorticoids are the most effective anti‐inflammatory therapy for asthma yet are relatively
ineffective in chronic obstructive pulmonary disease. Glucocorticoids suppress inflammation …

Glucocorticoids are the most effective anti-inflammatory therapy for many chronic
inflammatory and immune diseases, such as asthma, but are relatively ineffective in other …

The application of tumor immunotherapy to glioblastoma (GBM) is limited by an
unprecedented degree of immune suppression due to factors that include high numbers of …

Obesity is associated with a chronic low-grade inflammatory state that drives the
development of obesity-related co-morbidities such as insulin resistance/type 2 diabetes …

The recognition that there are some patients with features of asthma and chronic obstructive
pulmonary disease (COPD) has highlighted the need to develop more specific treatments for …

Macrophage migration inhibitory factor (MIF) emerged in recent years as an important
inflammation mediator, playing a prominent role in the pathogenesis of various types of …

Effective treatment of severe asthma is a major unmet need because patients' symptoms are
not controlled on maximum treatment with inhaled therapy. Asthma symptoms can be poorly …

Macrophage migration inhibitory factor (MIF) is a pleiotropic inflammatory cytokine that has
been implicated in various inflammatory diseases. Chronic inflammation is a mainstay of …